pirfenidone has been researched along with ER-Negative PR-Negative HER2-Negative Breast Cancer in 3 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 2 (66.67) | 24.3611 |
| 2020's | 1 (33.33) | 2.80 |
| Authors | Studies |
|---|---|
| Cheng, Z; Hu, Z; Li, D; Long, J; Long, S; Luo, D; Wang, Y; Zeng, X; Zeng, Z; Zhang, S; Zhou, J | 1 |
| Chen, G; Chitambar, CR; Dwinell, MB; Jing, W; Johnson, B; Lepp, A; Ma, S; Qi, X; Tang, J; Yin, N | 1 |
| Le, A; Takai, K; Weaver, VM; Werb, Z | 1 |
3 other study(ies) available for pirfenidone and ER-Negative PR-Negative HER2-Negative Breast Cancer
| Article | Year |
|---|---|
Pirfenidone suppressed triple-negative breast cancer metastasis by inhibiting the activity of the TGF-β/SMAD pathway.
Topics: Animals; Cell Line, Tumor; Cell Movement; Epithelial-Mesenchymal Transition; Humans; Mice; Signal Transduction; Smad Proteins; Transforming Growth Factor beta; Triple Negative Breast Neoplasms | 2023 |
p38γ MAPK Is a Therapeutic Target for Triple-Negative Breast Cancer by Stimulation of Cancer Stem-Like Cell Expansion.
Topics: Animals; Antineoplastic Agents; Cell Line, Tumor; Cell Proliferation; Female; HEK293 Cells; Humans; MCF-7 Cells; Mice, Inbred BALB C; Mice, Nude; Mitogen-Activated Protein Kinase 12; Neoplastic Stem Cells; Pyridones; Triple Negative Breast Neoplasms | 2015 |
Targeting the cancer-associated fibroblasts as a treatment in triple-negative breast cancer.
Topics: Animals; Antineoplastic Agents; Cancer-Associated Fibroblasts; Cell Line, Tumor; Cell Proliferation; Collagen; Dose-Response Relationship, Drug; Female; Humans; Lung Neoplasms; Mice, Inbred BALB C; Molecular Targeted Therapy; Pyridones; Signal Transduction; Time Factors; Transforming Growth Factor beta; Triple Negative Breast Neoplasms; Tumor Burden; Tumor Cells, Cultured; Tumor Microenvironment; Xenograft Model Antitumor Assays | 2016 |